Internet Computer
ICP
Bitcoin Cash
BCH
Litecoin
LTC
Specify Company / Ticker to Get the Summary
Internet Computer
ICP
Bitcoin Cash
BCH
Litecoin
LTC
Lyra Therapeutics Inc
LYRACurrent price
0.18 USD
+0.013 USD (+8.16%)
Last closed
0.16 USD
Company
lyratherapeutics.com
ISIN
US55234L1052
Sector
Healthcare
Industry
Biotechnology
Exchange
NASDAQ
Capitalization
12 148 930 USD
Yield for 12 month
-97.16 %
1Y
3Y
5Y
10Y
15Y
LYRA
Lyra Therapeutics, Inc., a clinical-stage biotechnology company, focuses on the development and commercialization of novel integrated drug and delivery solutions for the localized treatment of patients with ear, nose, and throat diseases. It's XTreo technology platform is designed to deliver medicines directly to the affected tissue for sustained periods with a single administration. The company's product candidates include LYR-210, an anti-inflammatory implantable drug matrix for the treatment of chronic rhinosinusitis (CRS), which is in Phase III clinical trial; and LYR-220 for CRS patients with and without nasal polyps. It has a collaboration agreement with LianBio Inflammatory Limited to develop and commercialize LYR-210 in mainland China, Hong Kong, Taiwan, Macau, South Korea, Singapore, and Thailand. The company was formerly known as 480 Biomedical, Inc. and changed its name to Lyra Therapeutics, Inc. in July 2018. Lyra Therapeutics, Inc. was incorporated in 2005 and is headquartered in Watertown, Massachusetts. Address: 480 Arsenal Way, Watertown, MA, United States, 02472
Check your investment idea
Find the best to beat the market
TSLA
Tesla Motors
AAPL
Apple
MSFT
Microsoft
Analytics
WallStreet Target Price
1.25 USDP/E ratio
–Dividend Yield
–Current Year
+1 558 000 USD
Last Year
+1 363 000 USD
Current Quarter
+195 000 USD
Last Quarter
+598 000 USD
Current Year
+1 558 000 USD
Last Year
+296 000 USD
Current Quarter
+195 000 USD
Last Quarter
-12 666 000 USD
Key Figures LYRA
1 year
3 years
5 years
10 years
EBITDA
-67 039 000 USD
Operating Margin TTM
Price to Earnings
–
Return On Assets TTM
-42.29 %
PEG Ratio
–
Return On Equity TTM
-186.18 %
Wall Street Target Price
1.25 USD
Revenue TTM
1 471 000 USD
Book Value
0.32 USD
Revenue Per Share TTM
Dividend Share
–
Quarterly Revenue Growth YOY
-64.20 %
Dividend Yield
–
Gross Profit TTM
-34 234 000 USD
Earnings per share
-1.51 USD
Diluted Eps TTM
-1.51 USD
Most Recent Quarter
III 2024
Quarterly Earnings Growth YOY
–
Profit Margin
–
Dividend Analytics LYRA
Max Ratio
>10 - expected double digit dividend yield on cost over 10Y >5 - expected 5-9 dividend yield on cost over 10Y <5 - expected <5 dividend yield on cost over 10Y MaxRatio is an estimated 10Y dividend yield on cost calculated by combining the current dividend yield with the 5-year & 10-year average dividend growth rate, projected over the next 10 years discounted based on current Financial Score. It provides a projected outlook on future dividend returns.
–5Y Dividend Growth
–Consecutive Years
–5Y Average Payout Ratio
–Dividend History LYRA
1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
Ex Dividend Date
–
Dividend CAGR 3Y
–
Dividend CAGR 5Y
–
Dividend CAGR 10Y
–
Consecutive Years
Consistent Years
Continuous Dividends
Forward Annual Dividend Yield
–
Forward Annual Dividend
– USD
Last Split Factor
–
Payout Ratio
–
Last Split Date
–
Stock Valuation LYRA
1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
Trailing PE
–
Forward PE
–
Enterprise Value Revenue
153.77
Price Sales TTM
8.26
Enterprise Value EBITDA
0.66
Price Book MRQ
0.59
Financials LYRA
1 year
3 years
5 years
10 years
15 years
| Results | 2019 | Dynamics |
* The data for this period has not yet been published
Technical indicators LYRA
For 52 weeks
0.16 USD
6.79 USD
50 Day MA
0.23 USD
Shares Short Prior Month
2 378 932
200 Day MA
1.46 USD
Short Ratio
0.89
Shares Short
2 202 963
Short Percent
4.20 %
BeatStart